NYSE$UNH

UnitedHealth · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

UnitedHealth Group's Q2 2024 performance reflected growth in revenues and earnings, but was impacted by cyberattack related costs and classification of South American operations as held for sale.

UnitedHealth Group reported Q2 2024 results with revenues of $98.9 billion, a $6 billion year-over-year increase led by Optum. Reported earnings were $4.54 per share, while adjusted earnings were $6.80 per share, including $0.28 in business disruption impacts. The company updated its full year 2024 net earnings outlook to $15.95 to $16.40 per share.

  • Revenues grew nearly $6 billion year-over-year to $98.9 billion, led by Optum.
  • Consumers served by UnitedHealthcare's commercial domestic offerings grew by 2.3 million year-to-date.
  • Cash flows from operations were $6.7 billion, 1.5 times net income.
  • Adjusted earnings of $6.80 per share include $0.28 in business disruption impacts and exclude South American and direct response costs.

Headline financials

Total Revenue

$98.9B

Previous: $92.9B+6.4%
EPS

$4.54

Previous: $6.14-26.1%
Medical Cost Ratio

85.1%

No prior period
Operating Cost Ratio

13.3%

No prior period
Optum Health Consumers

104.0M

No prior period
Optum Insight Backlog

$32.6B

No prior period
Optum Rx Scripts

399.0M

No prior period
Capital Expenditures

-$1.6B

Previous: -$1.59B-0.4%
Free Cash Flow

$2.62B

Previous: $3.89B-32.6%
Net Income

$4.22B

Previous: $5.47B-23.0%
Operating Income

$7.88B

Previous: $8.06B-2.3%
Gross Profit

$87.5B

Previous: $83.2B+5.2%
Cash & Equivalents

$26.3B

Previous: $41.8B-37.1%
Total Assets

$286B

Previous: $280B+2.1%
Stock-Based Comp

$222M

Previous: $242M-8.3%

Revenue & EPS history

UnitedHealth · Revenue · Quarterly

$98.9B

Q2 2024+6.4%vs Q2 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

UnitedHealth · $92.4B total across 4 segments · Q3 2023

  • Premiums
    $72.3B+12.2%
  • Products
    $10.4B+12.7%
  • Services
    $8.67B+29.4%
  • Investment & Other
    $997M+94.3%

Forward guidance

The company updated its full year 2024 net earnings outlook to $15.95 to $16.40 per share to reflect the classification to held for sale of its remaining South America operations and the estimated Change Healthcare cyberattack impacts. The company affirmed the adjusted net earnings outlook of $27.50 to $28.00 per share established at its November 2023 Investor Conference.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.9%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+2.6%

Avg return

30 days after

63%

46 / 73 earnings

Positive

+11.2%

Q2 2024

Best reaction

-22.4%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.2%+9.7%+18.1%
Q4 2025-11.2%-18.4%-18.5%
Q3 2025+0.1%-6.7%-9.9%
Q2 2025+0.6%+21.2%+38.2%
Q1 2025-22.4%-27.0%-50.1%
Q4 2024-6.2%-3.4%-3.7%
Q3 2024-5.6%-5.9%-2.0%
Q2 2024+11.2%+9.7%+12.5%
Q1 2024+7.5%+12.5%+17.0%
Q4 2023-3.8%-2.7%-4.0%
Q3 2023+2.4%+2.0%+3.0%
Q2 2023+8.1%+12.5%+13.5%
Q1 2023-4.0%-7.6%-6.7%
Q4 2022-2.1%-3.9%-0.3%
Q3 2022+2.3%+2.0%+2.4%
Q2 2022+3.4%+3.4%+8.2%
Q1 2022-0.5%+0.1%-9.6%
Q4 2021+0.4%+0.3%+1.5%
Q3 2021+6.1%+5.2%+13.7%
Q2 2021+1.2%-0.4%-1.2%
Q1 2021+4.1%+5.6%+9.1%
Q4 2020+0.8%-1.2%-7.8%
Q3 2020-2.1%-2.2%+7.3%
Q2 2020-0.4%-1.6%+4.9%
Q1 2020+10.3%+4.3%+7.6%
Q4 2019+4.3%+3.5%+3.7%
Q3 2019+7.4%+11.2%+16.0%
Q2 2019-3.8%-4.4%-7.9%
Q1 2019-5.8%-3.7%+2.9%
Q4 2018+5.4%+7.0%+7.0%
Q3 2018+2.7%+1.9%+1.8%
Q2 2018-0.6%-1.7%+2.4%
Q1 2018+2.6%+2.1%+5.5%
Q4 2017+4.3%+6.4%-1.1%
Q3 2017+6.2%+7.4%+9.3%
Q2 2017+1.5%+2.9%+3.4%
Q1 2017+1.2%+2.4%+2.6%
Q4 2016-2.5%-1.9%+1.1%
Q3 2016+7.6%+8.4%+12.4%
Q2 2016+1.6%+2.1%+1.0%
Q1 2016+4.8%
Q4 2015+5.1%
Q3 2015-1.7%
Q2 2015-1.6%
Q1 2015+1.2%
Q4 2014+7.8%
Q3 2014+7.3%
Q2 2014+2.1%
Q1 2014-4.1%
Q4 2013-3.1%
Q3 2013-8.6%
Q2 2013+7.9%
Q1 2013-3.2%
Q4 2012+1.7%
Q3 2012-2.6%
Q2 2012-1.7%
Q1 2012+3.8%
Q4 2011+2.3%
Q3 2011-2.2%
Q2 2011-1.7%
Q1 2011+0.5%
Q4 2010+0.7%
Q3 2010-0.5%
Q2 2010+1.6%
Q1 2009-0.8%
Q1 2010-0.2%
Q4 2009+0.4%
Q4 2007+0.4%
Q3 2008+5.5%
Q3 2009+5.5%
Q4 2008+1.3%
Q2 2008+1.3%
Q2 2009+1.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro